PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2028270
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2028270
Hepatitis B Vaccine Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of hepatitis B vaccine Market
The global hepatitis B vaccine market is experiencing steady expansion due to rising infection prevalence, increasing government immunization programs, and strong R&D investments in combination vaccine development. According to industry estimates, the market was valued at USD 9.34 billion in 2025 and is projected to reach USD 9.87 billion in 2026, further expanding to USD 15.54 billion by 2034, registering a CAGR of 5.83% during 2026-2034.
Market Size and Value Overview
The growth of the hepatitis B vaccine market is primarily driven by the global burden of hepatitis B virus (HBV) infections. According to the World Health Organization (WHO), around 296 million people were living with chronic hepatitis B in 2019, with approximately 1.5 million new infections annually (2023 estimate). This significant disease burden continues to create sustained demand for preventive vaccination programs worldwide.
In 2025, North America dominated the global market with a value of USD 3.12 billion, accounting for 33.38% of total market share. The region is projected to reach USD 3.27 billion in 2026, supported by strong healthcare infrastructure, early adoption of advanced vaccines, and government-led hepatitis elimination strategies.
Regional Insights
North America remains the leading regional market due to high awareness, strong vaccination coverage, and active public health policies. The United States continues to expand vaccination access through FDA fast-track approvals and new combination vaccine introductions.
Asia Pacific is the second-largest market, valued at USD 3.05 billion in 2025, and projected to reach USD 3.24 billion in 2026. This region is expected to witness the fastest growth due to high population density, rising HBV prevalence, and expanding immunization programs in countries such as China and India.
Europe accounted for USD 2.02 billion in 2025 and is expected to reach USD 2.14 billion in 2026, driven by strong newborn vaccination coverage across more than 50 countries. Meanwhile, the Rest of the World (Latin America and Middle East & Africa) is gradually expanding due to increasing awareness and government-led vaccination campaigns.
Market Drivers
A major growth driver is the increasing prevalence of hepatitis B infection globally. HBV is responsible for severe liver diseases such as cirrhosis and hepatocellular carcinoma. Transmission occurs through infected blood and maternal-to-child transmission, making newborn vaccination critical.
Government-led elimination programs are also significantly boosting market growth. For example, European and WHO-supported initiatives have achieved high infant vaccination coverage and improved screening of pregnant women, reducing infection rates in several regions.
Another key driver is the increasing adoption of combination vaccines, which provide protection against multiple diseases, improving immunization efficiency and patient compliance.
Industry Developments and Key Companies
The hepatitis B vaccine market is highly competitive, with leading pharmaceutical companies focusing on innovation, partnerships, and expansion of production capacity.
Key companies include:
- Sanofi, which continues to expand vaccine manufacturing infrastructure globally and invest heavily in advanced production technologies.
- GlaxoSmithKline plc, actively involved in hepatitis vaccine distribution and global immunization programs.
- Merck & Co., Inc., contributing to combination vaccine development and global supply.
- Dynavax Technologies, known for its recombinant hepatitis B vaccine HEPLISAV-B.
- VBI Vaccines Inc., focusing on innovative multi-antigen hepatitis B vaccines like PreHevbrio.
- Gilead Sciences, Inc., engaged in therapeutic research and combination treatment strategies.
- Chinese manufacturers such as SINOVAC and other biotech firms are expanding production capacity to meet rising domestic and global demand.
Market Segmentation Trends
By type, the combination vaccine segment dominates the market, accounting for 61.18% share in 2026, due to improved immunogenicity, cost-effectiveness, and broader disease protection. Single-antigen vaccines also maintain strong demand, especially in pediatric immunization programs.
By distribution channel, hospitals and retail pharmacies hold the largest share at 64.69% in 2026, as newborn vaccination is commonly administered in healthcare facilities. Government suppliers also play a crucial role, projected to hold around 65% share, driven by national immunization programs and global health initiatives.
Conclusion
Between 2025 and 2034, the hepatitis B vaccine market is expected to grow steadily from USD 9.34 billion to USD 15.54 billion, driven by rising global infection rates, strong immunization policies, and continuous innovation in vaccine technologies. With expanding government support and increasing adoption of combination vaccines, the market presents significant long-term growth opportunities for pharmaceutical companies worldwide.
Segmentation
By Type
- Single Antigen
- Combination
By Distribution Channel
- Hospitals
- Government Suppliers
- Others
By Region
- North America (By Type, Distribution Channel, and Country)
- U.S. (By Type)
- Canada (By Type)
- Europe (By Type, Distribution Channel, and Country)
- Germany (By Type)
- France (By Type)
- U.K. (By Type)
- Spain (By Type)
- Italy (By Type)
- Rest of Europe (By Type)
- Asia Pacific (By Type, Distribution Channel, and Country)
- China (By Type)
- India (By Type)
- Japan (By Type)
- Australia (By Type)
- Southeast Asia (By Type)
- Rest of Asia Pacific (By Type)
- Rest of the World (By Type, Distribution Channel, and Country)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Hepatitis B, By Key Countries 2025/2025
- 4.2. Pipeline Analysis, Key Players
- 4.3. Key Industry Developments, Mergers, Acquisitions, New Product Launches, Etc.
- 4.4. Impact of COVID-19 on the Market
5. Global Hepatitis B Vaccine Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Single Antigen
- 5.1.2. Combination
- 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.2.1. Hospitals & Clinics
- 5.2.2. Government Suppliers
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast - By Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Rest of the World
6. North America Hepatitis B Vaccine Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Single Antigen
- 6.1.2. Combination
- 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.2.1. Hospitals & Clinics
- 6.2.2. Government Suppliers
- 6.2.3. Others
- 6.3. Market Analysis, Insights and Forecast - By Country
- 6.3.1. U.S.
- 6.3.1.1. By Type
- 6.3.2. Canada
- 6.3.2.1. By Type
- 6.3.1. U.S.
7. Europe Hepatitis B Vaccine Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Single Antigen
- 7.1.2. Combination
- 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.2.1. Hospitals & Clinics
- 7.2.2. Government Suppliers
- 7.2.3. Others
- 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 7.3.1. Germany
- 7.3.1.1. By Type
- 7.3.2. France
- 7.3.2.1. By Type
- 7.3.3. U.K
- 7.3.3.1. By Type
- 7.3.4. Spain
- 7.3.4.1. By Type
- 7.3.5. Italy
- 7.3.5.1. By Type
- 7.3.6. Rest of Europe
- 7.3.6.1. By Type
- 7.3.1. Germany
8. Asia Pacific Hepatitis B Vaccine Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Single Antigen
- 8.1.2. Combination
- 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.2.1. Hospitals & Clinics
- 8.2.2. Government Suppliers
- 8.2.3. Others
- 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 8.3.1. China
- 8.3.1.1. By Type
- 8.3.2. India
- 8.3.2.1. By Type
- 8.3.3. Southeast Asia
- 8.3.3.1. By Type
- 8.3.4. Japan
- 8.3.4.1. By Type
- 8.3.5. Australia
- 8.3.5.1. By Type
- 8.3.6. Rest of Asia Pacific
- 8.3.6.1. By Type
- 8.3.1. China
9. Rest of the World Hepatitis B Vaccine Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Single Antigen
- 9.1.2. Combination
- 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.2.1. Hospitals & Clinics
- 9.2.2. Government Suppliers
- 9.2.3. Others
10. Competitive Analysis
- 10.1. Global Market Share Analysis (2025)
- 10.2. Company Profiles
- 10.2.1. GSK plc
- 10.2.1.1. Overview
- 10.2.1.2. Products & Services
- 10.2.1.3. SWOT Analysis
- 10.2.1.4. Recent Developments
- 10.2.1.5. Strategies
- 10.2.1.6. Financials (Based on Availability)
- 10.2.2. DYNAVAX TECHNOLOGIES
- 10.2.2.1. Overview
- 10.2.2.2. Products & Services
- 10.2.2.3. SWOT Analysis
- 10.2.2.4. Recent Developments
- 10.2.2.5. Strategies
- 10.2.2.6. Financials (Based on Availability)
- 10.2.3. VBI Vaccines Inc.
- 10.2.3.1. Overview
- 10.2.3.2. Products & Services
- 10.2.3.3. SWOT Analysis
- 10.2.3.4. Recent Developments
- 10.2.3.5. Strategies
- 10.2.3.6. Financials (Based on Availability)
- 10.2.4. Sanofi
- 10.2.4.1. Overview
- 10.2.4.2. Products & Services
- 10.2.4.3. SWOT Analysis
- 10.2.4.4. Recent Developments
- 10.2.4.5. Strategies
- 10.2.4.6. Financials (Based on Availability)
- 10.2.5. Merck & Co., Inc.
- 10.2.5.1. Overview
- 10.2.5.2. Products & Services
- 10.2.5.3. SWOT Analysis
- 10.2.5.4. Recent Developments
- 10.2.5.5. Strategies
- 10.2.5.6. Financials (Based on Availability)
- 10.2.6. Beijing Minhai Biological Technology Co., Ltd.
- 10.2.6.1. Overview
- 10.2.6.2. Products & Services
- 10.2.6.3. SWOT Analysis
- 10.2.6.4. Recent Developments
- 10.2.6.5. Strategies
- 10.2.6.6. Financials (Based on Availability)
- 10.2.7. Gilead Sciences, Inc.
- 10.2.7.1. Overview
- 10.2.7.2. Products & Services
- 10.2.7.3. SWOT Analysis
- 10.2.7.4. Recent Developments
- 10.2.7.5. Strategies
- 10.2.7.6. Financials (Based on Availability)
- 10.2.8. Beijing Tiantan Biological Products Co., Ltd.
- 10.2.8.1. Overview
- 10.2.8.2. Products & Services
- 10.2.8.3. SWOT Analysis
- 10.2.8.4. Recent Developments
- 10.2.8.5. Strategies
- 10.2.8.6. Financials (Based on Availability)
- 10.2.9. Amy Vaccine Co., Ltd.
- 10.2.9.1. Overview
- 10.2.9.2. Products & Services
- 10.2.9.3. SWOT Analysis
- 10.2.9.4. Recent Developments
- 10.2.9.5. Strategies
- 10.2.9.6. Financials (Based on Availability)
- 10.2.10. Biokangtai
- 10.2.10.1. Overview
- 10.2.10.2. Products & Services
- 10.2.10.3. SWOT Analysis
- 10.2.10.4. Recent Developments
- 10.2.10.5. Strategies
- 10.2.10.6. Financials (Based on Availability)
- 10.2.1. GSK plc
List of Tables
- Table 01: Global Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 02: Global Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 03: Global Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Region, 2021-2034
- Table 04: North America Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 05: North America Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 06: North America Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 07: U.S. Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 08: Canada Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 09: Europe Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 10: Europe Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 11: Europe Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
- Table 12: Germany Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 13: France Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 14: U.K. Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 15: Spain Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 16: Italy Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 17: Rest of Europe Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 18: Asia Pacific Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 19: Asia Pacific Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 20: Asia Pacific Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
- Table 21: China Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 22: India Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 23: Southeast Asia Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 24: Japan Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 25: Australia Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 26: Rest of Asia Pacific Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 27: Rest of the World Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 28: Rest of the World Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
List of Figures
- Figure 01: Global Hepatitis B Vaccine Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 02: Global Hepatitis B Vaccine Market Value Share (%), By Type, 2025 & 2034
- Figure 03: Global Hepatitis B Vaccine Market Value Share (%), By Distribution Channel, 2025 & 2034
- Figure 04: Global Hepatitis B Vaccine Market Value Share (%), By Region, 2025 & 2034
- Figure 05: North America Hepatitis B Vaccine Market Value (USD billion), by Type, 2025 & 2034
- Figure 06: North America Hepatitis B Vaccine Market Value Share (%), by Type, 2025
- Figure 07: North America Hepatitis B Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 08: North America Hepatitis B Vaccine Market Value Share (%), by Distribution Channel, 2025
- Figure 09: North America Hepatitis B Vaccine Market Value (USD billion), by Country, 2025 & 2034
- Figure 10: North America Hepatitis B Vaccine Market Value Share (%), by Country, 2025
- Figure 11: Europe Hepatitis B Vaccine Market Value (USD billion), by Type, 2025 & 2034
- Figure 12: Europe Hepatitis B Vaccine Market Value Share (%), by Type, 2025
- Figure 13: Europe Hepatitis B Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 14: Europe Hepatitis B Vaccine Market Value Share (%), by Distribution Channel, 2025
- Figure 15: Europe Hepatitis B Vaccine Market Value (USD billion), by Country/Sub-region, 2025 & 2034
- Figure 16: Europe Hepatitis B Vaccine Market Value Share (%), by Country/Sub-region, 2025
- Figure 17: Asia Pacific Hepatitis B Vaccine Market Value (USD billion), by Type, 2025 & 2034
- Figure 18: Asia Pacific Hepatitis B Vaccine Market Value Share (%), by Type, 2025
- Figure 19: Asia Pacific Hepatitis B Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 20: Asia Pacific Hepatitis B Vaccine Market Value Share (%), by Distribution Channel, 2025
- Figure 21: Asia Pacific Hepatitis B Vaccine Market Value (USD billion), by Country/Sub-region, 2025 & 2034
- Figure 22: Asia Pacific Hepatitis B Vaccine Market Value Share (%), by Country/Sub-region, 2025
- Figure 23: Rest of the World Hepatitis B Vaccine Market Value (USD billion), by Type, 2025 & 2034
- Figure 24: Rest of the World Hepatitis B Vaccine Market Value Share (%), by Type, 2025
- Figure 25: Rest of the World Hepatitis B Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 26: Rest of the World Hepatitis B Vaccine Market Value Share (%), by Distribution Channel, 2025
- Figure 27: Global Hepatitis B Vaccines Market Share Analysis (%), By Company, 2025
